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The Ethics of IVF 
Abstract 
In vitro fertilization (IVF) has promised hope to many couples struggling with the pain of infertility. 
However, as with any new medical technology, the ethical implications of this procedure must be 
examined, particularly in light of recent events such as the birth of the first genetically modified human 
beings, made possible by IVF. It is crucial to examine oppositions to IVF based on principle, as well as 
address concerns related to adjacent issues such as the discard of unused embryos; the selection, 
payment, privacy, and parental rights of donors and surrogates; the importance of genetic parenthood; 
new combinations of gametes; preimplantation genetic diagnosis and selective implantation; and 
economic incentives. Short-term justifications shape long-term values, and so we must carefully consider 
the implications of IVF, even as we maintain compassion and grace toward couples dealing with the 
difficult realities of infertility. 
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Direction Determines Destination: The Ethics of IVF 
Breanna Beers 
Cedarville University 
Introduction 
Since the birth of Louise Brown in 1978,1 in vitro fertilization (IVF) has become a widely accepted 
infertility treatment option. It’s an expensive and involved procedure, typically only sought out when other 
fertility therapies fail. By allowing fertilization to take place in a highly controlled environment using only 
healthy gametes, IVF gave hope to many couples who previously had no further recourse for treatment.  
The IVF procedure takes place over several weeks, timed according to the would-be mother’s menstrual 
cycle. Couples undergo a number of pre-cycle tests to identify any relevant factors that may influence 
treatment.2 Treatment protocol often varies among individuals, but women wishing to conceive typically 
take birth control pills for several days or weeks before beginning a cycle in order to control cycle timing, 
follicle development, or other factors.  
Once it is time for the treatment cycle to begin, ovulation is stimulated using gonadotropins and a 
gonadotropin-releasing hormone (GnRH) agonist or antagonist.3 Gonadotropins are hormones that play a 
role in stimulating egg production in women; the GnRH agonist or antagonist prevents the dominant oocyte 
follicle(s) from being ovulated before the others have time to fully develop. This combination allows as 
many mature eggs as possible to be obtained.4 
Next, the eggs must be retrieved from the ovaries. About 36 hours before the procedure, ovulation is induced 
by taking human chorionic gonadotropin. A needle is inserted up the vagina and through the vaginal wall 
to puncture the ovary. The follicular fluid is then extracted and taken to the laboratory to isolate the eggs. 
Usually, the patient is under anesthesia during this procedure.5 
Once the eggs have been isolated, they are fertilized in vitro by either conventional fertilization or by 
intracytoplasmic sperm injection (ICSI). Under the conventional method, healthy sperm are isolated from 
the provided sample and simply exposed to the eggs for natural fertilization. ICSI involves manually 
injecting sperm into the egg, which may increase fertility rates, especially in cases of male-factor infertility.6 
ICSI is becoming an increasingly popular technique in many clinics; in 2012, more than three-quarters of 
 
1 Craig Niederberger et al., "Forty Years of IVF," Fertility and Sterility 110 (2018), 185-324. 
2 Craig Niederberger et al., "Forty Years of IVF," Fertility and Sterility 110 (2018), 185-324. 
3 Artur Wdowiak, Edyta Wdowiak and Iwona Bojar, "Improving the Safety of the Embryo and the Patient during in 
Vitro Fertilization Procedures," Wideochir Inne Tech Maloinwazyjne 11 (2016), 137-143. 
4 Qiaohong Lai et al., "Comparison of the GnRH Agonist and Antagonist Protocol on the Same Patients in Assisted 
Reproduction during Controlled Ovarian Stimulation Cycles," International Journal of Clinical and Experimental 
Pathology 6 (2013), 1903-1910. 
5 Wdowiak, "Improving the Safety of the Embryo and the Patient during in Vitro Fertilization Procedures," , 137-
143 
6 Craig Niederberger et al., "Forty Years of IVF," Fertility and Sterility 110 (2018), 185-324). 
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all IVF procedures were performed using ICSI.7 While some studies show that conventional fertilization 
may be preferred over ICSI in cases where male-factor fertility is not a concern,8 others have found that 
ICSI has similar results in cases with unexplained infertility as in cases with male-factor infertility.9 
The fertilized embryos are then cultured in an incubator until they can be transferred into the womb.10 
Embryos are allowed to grow for a few days in culture so they can be assessed for health and stability. 
Usually, only the one or two healthiest embryos are transferred to the womb in order to increase the chance 
of pregnancy; recently, many clinics have begun to particularly favor single-embryo transfer to reduce the 
risk of multiple births (twins, triplets, etc.). The unused embryos are then preserved for future cycles, 
donated for research, or discarded.11 
To transfer the embryo(s), a special catheter is inserted up the vagina and into the uterus to inject the embryo 
into the endometrium, the lining of the uterus where the embryo will hopefully implant. The invasiveness 
of this procedure varies among individuals.12 The fertility clinic typically follows up with the patient several 
times over the next few weeks until pregnancy can be determined, at which point care is transferred to the 
OB/GYN.  
The success rate of IVF varies widely from individual to individual. One 2012 UK study found that overall, 
the chances of achieving live birth after the first cycle of IVF were 29.5%, with just over two-thirds of 
women achieving live birth after six cycles (a significant finding since IVF treatment is typically halted 
after just three or four cycles).13 
In general, IVF outcomes worsen with age.14 The 2016 National Summary Report of the Society for 
Assisted Reproductive Technology reported that women under the age of 35 had just under a 50% chance 
of conceiving for any given cycle; women aged 35-37 had a 34.8% chance; women aged 38-40 had a 21.8% 
chance, and women over 40 had a less than 10% chance.15 
 
7 Hui Liu et al., "Conventional in Vitro Fertilization (IVF) Or Intracytoplasmic Sperm Injection (ICSI): Which is 
Preferred for Advanced Age Patients with Five Or Fewer Oocytes Retrieved?" Archives of Gynecology and 
Obstetrics 297 (2018), 1301-1306. 
8 Hui Liu et al., "Conventional in Vitro Fertilization (IVF) Or Intracytoplasmic Sperm Injection (ICSI): Which is 
Preferred for Advanced Age Patients with Five Or Fewer Oocytes Retrieved?" Archives of Gynecology and 
Obstetrics 297 (2018), 1301-1306. 
9 Wardah Alasmari et al., "Comparable Reproductive Outcomes of ICSI for Couples with Unexplained Infertility and 
Couples with Male Factor Infertility," 23 (2018), 393-398. Middle East Fertility Society Journal. 
10 Wdowiak, "Improving the Safety of the Embryo and the Patient during in Vitro Fertilization Procedures," , 137-
143 
11 Niederberger, "Forty Years of IVF," , 185-324 
12 Wdowiak, "Improving the Safety of the Embryo and the Patient during in Vitro Fertilization Procedures," , 137-
143 
13 Andrew Smith et al., "Live-Birth Rate Associated with Repeat in Vitro Fertilisation Treatment Cycles," The Journal 
of the American Medical Association 314 (2015), 2654-2662. 
14 Andrew Smith et al., "Live-Birth Rate Associated with Repeat in Vitro Fertilisation Treatment Cycles," The Journal 
of the American Medical Association 314 (2015), 2654-2662. 
15 (Niederberger and others 2018, 185-324). 
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IVF outcomes can also vary depending on whether one, two, or more embryos are transferred.16 
Transferring more embryos will increase the chances of a pregnancy, but is likely to result in twins or 
higher-order births.17 Multiple birth is significantly more dangerous for the mother, with a high risk of 
complications and potential need for cesarean section delivery.18 
Other physical risks of IVF include side effects of hormonal treatment, ovarian hyperstimulation syndrome 
during pre-treatment for egg retrieval,19 infection from retrieval or transfer procedures,20 and risks 
associated with pregnancy and delivery especially for older mothers. 
This paper will briefly summarize some historical ethical criticisms of IVF as a practice in itself. The bulk 
of the paper will then address the ethical significance of issues adjacent to IVF, including the personhood 
of embryos, preimplantation genetic diagnosis, gamete donation, surrogacy, new gamete combinations, 
insurance incentives, and the role of biological children. 
IVF and ethical traditions 
Some observers may oppose IVF prima facie, seeing any application of this technology as inherently 
unethical, even when used under the most conservative circumstances -- say, a heterosexual married couple 
for whom no other infertility treatment options are available, who only extract a few eggs from the wife 
and implant all embryos that result from fertilization with the husband’s sperm. While this paper will 
primarily focus on adjacent issues of alternative applications, these objections are worth addressing at the 
outset. 
The most common opposition to IVF in principle is based in natural law theory, which holds that “reason 
recognizes intrinsic goods persons seek for human fulfillment.”21 In other words, what is good can be 
logically deduced by observing what people naturally seek. This position was popularized by Thomas 
Aquinas and remains the predominant perspective of the Catholic church today.22 The Dignitas Personae, 
a 2008 instruction from the Catholic Congregation for the Doctrine of the Faith, gives a representative 
overview of the Catholic natural law position on bioethical issues, including IVF. Like other Catholic 
documents (most notably the Donum Vitae), this declaration condemns IVF because it separates 
reproduction from sexual intercourse between the husband and wife, bringing a deeply personal act into the 
 
16 V. E. Klenov, "Live Birth and Multiple Birth Rates in US in Vitro Fertilization Treatment using Donor Oocytes: A 
Comparison of Single-Embryo Transfer and Double-Embryo Transfer," Journal of Assisted Reproduction and 
Genetics 35 (2018), 1657-1664. 
17 Samer Tannus et al., "Cumulative Live Birth Rate Following Elective Single Blastocyst Transfer Compared with 
Double Blastocyst Transfer in Women Aged 40 Years and Over," Reproductive BioMedicine Online 35 (2017), 733-
738. 
18 Ammon Goldworth, "The Ethics of in Vitro Fertilization," Pediatrics in Review 20 (1999), 28-31. 
19 Wdowiak, "Improving the Safety of the Embryo and the Patient during in Vitro Fertilization Procedures," , 137-
143 
20 Artur Wdowiak, Edyta Wdowiak and Iwona Bojar, "Improving the Safety of the Embryo and the Patient during in 
Vitro Fertilization Procedures," Wideochir Inne Tech Maloinwazyjne 11 (2016), 137-143. 
21 N. Steffen, "Core Values in Bioethics: A Natural Law Perspective," Ethics, Medicine, and Public Health 2 (2016), 
170-180. 
22 D. A. Jones, "Christian Ethics, Roman Catholic," in Encyclopedia of Applied Ethics, Second Edition, ed. Ruth 
ChadwickElsevier, Inc., 2012), 435-444. 
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cold environment of the laboratory. The church maintains this position both on spiritual grounds that uphold 
the sacrament of marriage and on natural grounds that insist that reproduction inherently is and ought to be 
exclusively tied to sexual intercourse between husband and wife.23 The Dignitas Personae also specifically 
rejected the use of ICSI, the discard of unwanted embryos, the freezing of eggs and embryos, and 
preimplantation genetic diagnosis. 
Similarly, bioethicist Gilbert Meilaender argued that the biological bond between parent and child is of 
moral significance because 1) human beings are embodied in nature, 2) reproduction is at least one part of 
the purpose of the sexual union of husband and wife, and 3) children are meant to be a manifestation of the 
marital union of love, not the result of rational calculation and a purchased procedure.24 According to 
Meilander, the introduction of third parties into the procreative process -- be they physicians, donors, or 
surrogates -- violates the sacred nature of reproduction, blurs lines of kinship and family ties, fails to 
embody the union of the parents, instrumentalizes the human body, and turns the child into a product which 
is made, not begotten.25  
Others have opposed IVF on the grounds that it makes the child substitutable, a mere manufactured 
commodity. The child is sought as a means to fulfill the intended parents’ desires, rather than an end-in-
him/herself, violating the Kantian imperative. Bioethicist Robert George warned of this even outside the 
context of IVF: when considered rightly, children ought to be “treated by their parents, even in their 
conception, not as a means to their parents’ ends, but as ends-in-themselves; not as objects of the desire or 
will of their parents, but as subjects whose fundamental interests as human beings are protected by the 
principles of justice and human rights: not as property, but as persons.”26 
These views and others oppose IVF on principled grounds, claiming that even in the most ideal 
circumstances, IVF comes with a great moral cost, however genuinely good the result. Many of these claims 
are legitimate concerns that bear consideration; whatever the benefit to the individual, IVF has and certainly 
will continue to influence the shape of society -- our values, our morality, and our metaphysical beliefs. 
Where we as a society have landed on this issue will inevitably inform our answers to questions yet to 
come. 
This principle of present decisions shaping future values is worth keeping in mind as we explore adjacent 
issues in the rest of this paper: the filling-out of alternative applications to the ‘most conservative’ option 
described at the beginning of this section. Some are future projections likely just around the corner; many 
are presently practiced and crucially significant for our understanding of family, procreation, and humanity. 
Unused embryos and the beginning of life 
The single most significant ethical issue when considering the morality of IVF is the personhood of unused 
embryos. Almost always, more eggs are extracted and fertilized than mature and are transferred, as 
 
23 Congregation for the Doctrine of the Faith, "Dignitas Personae," (2008). 
24 Gilbert Meilaender, Bioethics: A Primer for Christians, 3rd ed. (Grand Rapids, Michigan: Eerdmans, 2013). 
25 Gilbert Meilaender, Bioethics: A Primer for Christians, 3rd ed. (Grand Rapids, Michigan: Eerdmans, 2013). 
26 (George )” 
13 
Bioethics in Faith and Practice ⦁ 2019 ⦁ Volume 4 ⦁ Number 1 
 
described above. This practice raises many significant ethical issues that have contributed to the abortion 
debate, still controversial in the U.S. nearly half a century after Roe vs. Wade. 
Defining what makes a person a person has been the central question of bioethics since the discipline’s 
beginning. In particular, the grey areas around birth and death have been the subject of both medical inquiry 
and philosophical contemplation. The definitive moment when a new person comes into existence has been 
argued to take place at conception, implantation, the point of brain development, the point at which the 
fetus can feel pain, the point at which the fetus would be viable outside the womb, and birth.  
Marking that moment requires a sufficient definition of what qualities and/or capacities it is, exactly, that 
make a living thing a person. The state of New York decided this year that a baby is a person only if his/her 
mother wanted him/her to exist, repealing any protection for babies born alive after an abortion attempt 
This implicitly affirmed a relational view of personhood, recognizing the humanity of the baby only if 
he/she is loved or wanted by someone else. While many celebrated the passing of this law, many others, 
including some who support abortion in other cases, mourned this legalization of infanticide.  
Others, such as the utilitarian philosopher Peter Singer,27 try to place personhood on a spectrum, often based 
on qualities such as intelligence, moral reasoning, consciousness, and/or self-awareness. This is troubling, 
however, since this definition necessitates that one adult human may be more of a “person” than another. 
Taken to Singer’s extremes, some animals may be classified as more valuable than some children and 
mentally disabled people. 
Attempts to mark the beginning of personhood as it relates to the human embryo face the challenge that 
while personhood should not be defined as a spectrum, development necessarily is. The brain develops over 
a period of time; sensitivity to pain likewise changes; viability is constantly being altered by changes in 
medical technology, while even a baby who is born alive is not viable without care. 
Implantation and conception are the only two clearly distinguishable markers that don’t constitute moving 
targets, and seem the only biologically defensible moral positions. Of the two, I tend to favor conception 
as the most likely moment for the creation of a new person for two reasons. First, when considering 
decisions such as selective embryo transfer or abortion,  the outcome is one of two ethical extremes: it is 
either morally permissible or it is murder. Since the potential harm if we choose incorrectly is so vast, I 
consider the morally right decision to be the more conservative one. Second, implantation is a change in 
location from the fallopian tubes to the wall of the uterus, while conception is a change in being (from two 
haploid, end-stage gametes to a new, genetically unique diploid cell). Conception is the point at which a 
new member of the human species is created, and I think that while the concepts of a person and a genetic 
human are not necessarily identical, the two concepts can generally be treated as united for practical 
purposes. 
While neither the implantation nor the conception view allows for traditional abortions, the distinction is 
significant when it comes to IVF. Discarded embryos are past the point of conception, but have not yet been 
implanted. As we move on to address other ethical issues surrounding IVF, it is crucial to remember that it 
is not only the interests of the infertile couple but also their created children that are at stake. 
 
27 John Hymers, "Not a Modest Proposal: Peter Singer and the Definition of Person," Ethical Perspectives 6 (1999), 
126-138. 
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Donors, surrogates, and new combinations of gametes 
Since IVF distances reproduction from the physical act of sex, it enables couples to conceive in ways no 
longer limited by anatomical practicalities. A summary of possible combinations of gamete donors and 
surrogates can be found in table 1. A full treatment of every possible situation is beyond the scope of this 
paper, as is the discussion of whether homosexual couples should become parents. Instead, I will briefly 
outline the IVF-specific issues associated with 1) gamete donation, 2) surrogacy, and 3) new combinations 
of gametes, eg. sperm + sperm and egg + egg.  
 
Gamete donation 
Artificial insemination using donor sperm has been practiced since at least the late 1800’s,28 and the first 
known egg donation occurred in Australia in 1983, just five years after the first IVF birth.29 Gamete 
donation provides couples with poor gamete quality the possibility of obtaining a child who is at least 
partially related and who can be carried to term by the would-be mother. While common, this practice raises 
significant ethical and legal questions regarding the relationships among the donor, recipients, and 
offspring.  
 
28 Willem Ombelet and Johan Van Robays, "Artificial Insemination History: Hurdles and Milestones," Facts, Views & 
Vision in ObGyn 7 (2015), 137. 
29 Daniel Shapiro, "Payment to Egg Donors is the Best Way to Ensure Supply Meets Demand," Best Practice & 
Research Clinical Obstetrics & Gynaecology 53 (2018), 73-84. 
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In the United States, sperm donors can be paid up to $125 per donation, depending on quality and/or 
quantity of usable sperm obtained.30 Men with in-demand characteristics (including ethnicity, education, 
etc.) can be paid more.31 Since the process for sperm donation is relatively simple, men can donate 
frequently, with some clinics offering up to $1,000 to $1,500 a month for frequent donors.32 
On average, egg donors are paid up to $10,000 or more,33 but can donate only a few times at most, and have 
to undergo a fairly invasive procedure for extraction. Typically, egg donors undergo retrieval just as the 
would-be mother would in a non-donor IVF cycle: stimulation of ovulation followed by the in-clinic 
extraction procedure, with an average of about 13 eggs obtained. This does pose some risk of ovarian 
hyperstimulation syndrome and related side effects.34 
The question of paying gamete donors at all has been a controversial one. In many ways, this practice 
reflects the growing trend of medical consumerism.35 Some argue that paying donors commodifies 
reproduction and makes children into a mere product.36 Others hold that given the time and, in the case of 
egg donors, risk and pain required to donate, it would be unjust for donors not to be compensated; further, 
sufficient high-quality gametes would not be available without incentivizing donation in some way.37 
Also tied to the consumer trend in medicine is the question of whether couples should be permitted to 
choose the sperm/egg donor for their child. Typically, sperm banks collect various information about 
donors, biological and otherwise. Medical anthropologist Diane Tober describes a lesbian couple who 
described their sperm donor as “a doctor, 6 foot 4 inches, [who] played basketball and drank coffee.”38 
Medical information is always required for the sake of producing a healthy child, but donor profiles also 
often include secondary characteristics. For instance, recipients can choose a donor according to biological 
traits such as height, ethnicity, etc., as well as personal information like career, hobbies, and habits. 
Both recipients and repositories select sperm donors based on a particular profile. As Tober observed, 
“Sperm donation, then, provides a window to reproductive values and a social/moral system, as well as the 
dynamics between culture and biology.” This practice seems to indicate that certain traits are valued more 
highly than others and worth selecting for when choosing how to produce a child (the same considerations 
apply in the case of egg donation). Often, recipients choose donors of the same ethnic and educational 
background as themselves.39 
 
30 An Ravelingien et al., "Recipients' Views on Payment of Sperm Donors," Reproductive BioMedicine Online 31 
(2015), 225-231. 
31 Diane Tober, "Semen as Gift, Semen as Goods: Reproductive Workers and the Market in Altruism," Body and 
Society 7 (2001), 137-160. 
32 Ravelingien, "Recipients' Views on Payment of Sperm Donors," , 225-231 
33 Shapiro, "Payment to Egg Donors is the Best Way to Ensure Supply Meets Demand," , 73-84 
34 Cynthia Cohen, "Reproductive Technologies: V. Gamete Donation," in Encyclopedia of Bioethics, 2004). 
35 Liz Meerabeau, "Consumerism and Health Care: The Example of Fertility Treatment," Journal of Advanced 
Nursing 27 (1998), 721-729. 
36 Meilaender, Bioethics: A Primer for Christians 
37 Shapiro, "Payment to Egg Donors is the Best Way to Ensure Supply Meets Demand," , 73-84 
38 Tober, "Semen as Gift, Semen as Goods: Reproductive Workers and the Market in Altruism," , 137-160 
39 Diane Tober, "Semen as Gift, Semen as Goods: Reproductive Workers and the Market in Altruism," Body and 
Society 7 (2001), 137-160. 
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In traditional reproduction, an individual has the opportunity to select whom he or she would like to 
reproduce with; however, in most cases, selection is based on the desire for intimacy  rather than to 
strategically produce an optimal child. In the minds of some, this leans dangerously close to eugenics. At 
the same time, however, the significance of producing a child with the genetic material of a stranger seems 
to warrant some amount of patient choice.  
The anonymity of donors has historically been a toss-up when it comes to law. Anonymous donation is an 
established norm in many places, and protected by law in some countries including Spain, France, and 
Denmark. However, Norway, Sweden, the Netherlands, and the UK, among other countries, require donors 
to be identifiable to their potential genetic offspring.40 Advocates of anonymity emphasize the protection 
of the donors’ interest in privacy and the recipients’ interest in providing what they believe to be the best 
care for their future child, not wanting to create doubt in his or her identity or weaken family ties. Critics, 
however, claim that children have a right to know where their genetic information comes from, and even 
seek out their genetic parent if they so choose. However, giving children this right is controversial in itself, 
even if donors are mandated to be identifiable. Donors typically don’t see themselves as parents and don’t 
wish to be thought of as bearing any responsibility to the offspring that are produced with their DNA. 
Much of this discussion raises broader questions about the significance of genetics to family relationships 
and parenthood -- questions that never before demanded an answer, but that have already and will continue 
to be significant in the shaping of society, so long as family remains the building block of which it is made. 
This includes whether introducing a third party to the act of reproduction impacts a marriage, the 
significance of IVF over adoption when the child will ultimately only be partly related, and whether there 
is any obligation between parents and their genetic offspring. 
Surrogacy 
While the concept of anonymity is out of the question, surrogacy deals with the same difficulties of 
compensation and selection as donation, magnified a hundredfold. While egg donation is a fairly invasive 
procedure, gestation is a far more intrusive burden on everyday life and demands a full three-quarters of a 
year. 
Surrogacy removes not only conception, but childbearing itself from the context of the family. Sometimes, 
parents may have extra embryos left from previous failed IVF cycles, and choose to transfer to a surrogate 
instead of the intended mother with the hope of increasing the likelihood of pregnancy. However, in most 
cases when a surrogate is needed, only one of the intended parents can contribute genetic material at all. 
This raises even more questions about the role of genetics and family. What is the significance of biological 
children? If a child is going to be only 50% genetically related to the couple and will not be borne by the 
intended mother, what is the importance of conceiving this way as opposed to adoption? To what extent is 
the rise of surrogacy influenced by the broader trend of a desire for extreme control over the family-building 
process, and how far should that control be taken? 
 
40 Immaculada De Melo-Martín, "How Best to Protect the Vital Interests of Donor-Conceived Individuals: 
Prohibiting Or Mandating Anonymity in Gamete Donations?" Reproductive Biomedicine & Society Online 3 (2016), 
100-108. 
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New combinations of gametes 
Over the last few years, numerous studies have explored the possibility of new combinations of gametes to 
form an embryo, eliminating the need for either sperm or egg. For instance, in 2001, Australian scientists 
successfully injected somatic cells into mouse eggs to form embryos, although developmental viability was 
limited.41 In 2016, scientists from the University of Bath demonstrated that parthenogenotes (unfertilized 
eggs that are tricked into developing like an embryo while remaining haploid) are capable of being fertilized 
by sperm; authors posited that any somatic cell with half its genetic material removed should be able to 
undergo the same process, removing the need for an egg.42 In 2017, University of Cambridge scientists used 
embryonic mouse stem cells to mimic in-vitro embryogenesis.43 In 2018, a study published in the journal 
Nature performed a similar process with human stem cells to produce a “blastocyst-like structure.”44 If this 
technology were to be developed and popularized, the requirement for both male and female genetic parents 
could be eliminated, further changing the historically fundamental structure of family and kinship ties. 
Preimplantation genetic diagnosis and selective implantation 
Preimplantation genetic diagnosis, or PGD, has been used in conjunction with IVF since 1990.45 It’s a form 
of genetic screening that allows physicians to detect monogenic (Mendelian) diseases, conditions which 
result from one or a very few mutations at known loci in the genome. Records are unclear on how common 
PGD is in the United States, but the practice is often recommended for couples with a history of genetic 
disease.46  
Background 
DNA for PGD can be obtained at several stages of early development, including before the embryo is even 
formed. Polar bodies, the inert cells created alongside the egg during meiosis, can be safely removed and 
examined for aneuploidy,47 the condition of having the incorrect number of chromosomes due to 
nondisjunction. Aneuploidy in a polar body often but not always indicates aneuploidy in the egg, which 
typically results in a failed pregnancy. This is a common problem for older women trying to conceive.48 
Examining polar bodies for some monogenic diseases has also been used to deduce the genotype of the egg 
with up to 97% accuracy.49 Polar body biopsy may allow higher rates of pregnancy while avoiding some of 
 
41 Orly Lacham-Kaplan, Rob Daniels and Alan Trounson, "Fertilization of Mouse Oocytes using Somatic Cells as 
Male Germ Cells," Reproductive BioMedicine Online 3 (2001), 205-211. 
42 Toru Suzuki et al., "Mice Produced by Mitotic Reprogramming of Sperm Injected into Haploid Parthenogenotes," 
Nature Communications 7 (2016), 1-15. 
43 Sarah Ellys Harrison et al., "Assembly of Embryonic and Extraembryonic Stem Cells to Mimic Embryogenesis in 
Vitro," Science 14 (2017). 
44 Nicolas Rivron et al., "Blastocyst-Like Structures Generated Solely from Stem Cells," Nature 557 (2018), 106-111. 
45 Niederberger, "Forty Years of IVF," , 185-324 
46 Susannah Baruch, David Kaufman and Kathy Hudson, "Genetic Testing of Embryos: Practices and Perspectives of 
US in Vitro Fertilization Clinics," Fertility and Sterility 89 (2008), 1053-1058. 
47 Markus Montag et al., "Polar Body Biopsy," Fertility and Sterility 3 (2013), 603-607. 
48 Marie MacLennan et al., "Oocyte Development, Meiosis and Aneuploidy," Seminars in Cell and Developmental 
Biology 45 (2015), 68-76. 
49 Karen Sermon, André Van Steirteghem and Inge Liebaers, "Preimplantation Genetic Diagnosis," The Lancet 363 
(2004), 1633-1641. 
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the difficult ethical issues around personhood and conception, as polar bodies are not necessary for 
fertilization or embryonic development,50 and any selection would occur before fertilization.  
Polar body biopsy has its limitations, however. Since only the mother’s genetic information is considered, 
it can only determine oocyte aneuploidy and, in some cases, recessive monogenic diseases. For recessive 
conditions, the father’s genetic contribution could render the child either homozygously healthy or a 
heterozygous carrier, but as long as the dominant normal allele from the mother is present, the child should 
experience minimal ill effects. For dominant Mendelian conditions, however, a normal oocyte cannot 
guarantee a healthy child, as the father’s allele alone could cause the full effects of the disease. 
For this reason, other forms of genetic screening are often used instead of or in conjunction with polar body 
biopsy. Cleavage-stage biopsy allows embryos to grow in vitro for a few days until they reach their third 
division, when six or more cells are present. One or two cells are then extracted from each embryo for 
genetic examination. This typically involves polymerase chain reaction (PCR) amplification at the gene of 
interest followed by fluorescence in situ hybridization (FISH) to identify the presence or absence of a 
specific sequence. Cleavage-stage biopsy is the most common method of PGD,51 since it allows direct 
examination at a variety of loci in the embryo itself, avoiding the major disadvantages of polar body biopsy. 
However, only one or two cells can be extracted, so accuracy may be compromised by chromosomal 
mosaicism and PCR sensitivity. There is little consensus on the best number of cells to extract, as extracting 
more cells gives greater diagnostic accuracy, but may reduce the embryo’s ability to implant and develop 
normally.52 
Some clinics have begun to increasingly use blastocyst biopsy as an alternative to cleavage-stage biopsy.53 
At this stage, the embryo consists of just over 100 cells, so more cells can be removed. This can lower the 
risk of PCR failure, which renders no result, or allele dropout, which gives incomplete results. However, 
only 36-66% of embryos mature this far in vitro.54 Further, since embryos must be transferred to the womb 
within 5 or 6 days of extraction, blastocyst biopsy leaves little time for removal and diagnosis.55  
Since cells are removed from the trophectoderm, a portion of the blastocyst that primarily contributes to 
the formation of placental tissue rather than the developing embryo, blastocyst biopsy is expected to have 
little effect on embryonic development.56 In fact, one study found that while cleavage-stage biopsy resulted 
in a 39% decline in implantation outcomes relative to non-biopsied cells, while blastocyst (trophectoderm) 
 
50 Montag, "Polar Body Biopsy," , 603-607 
51 C. Moutou et al., "ESHRE PGD Consortium Data Collection XII: Cycles from January to December 2009 with 
Pregnancy Follow-Up to October 2010," Human Reproduction 29 (2014), 880-903. 
52 Alan Thornhill, Practice Manual of in Vitro Fertilization (New York: Springer, 2012). 
53 Niederberger, "Forty Years of IVF," , 185-324 
54 G. Kokkali et al., "Blastocyst Biopsy Versus Cleavage Stage Biopsy and Blastocyst Transfer for Preimplantation 
Genetic Diagnosis of Β-Thalassaemia: A Pilot Study," Human Reproduction 22 (2007), 1443-1449. 
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biopsy “had no meaningful impact on the developmental competence of the embryo as measured by 
implantation and delivery rates.”57 
The comparatively high implantation failure of cleavage-stage biopsy for PGD is troubling on a practical 
level for those trying to conceive, as well as on a moral level if life begins at conception. However, polar 
body biopsy is limited in application and blastocyst biopsy faces challenges in both embryo survival and 
procedure completion time. Yet even if biopsy can be completed efficiently without harming the growing 
embryo, there are significant ethical questions surrounding the practice of PGD itself. 
Ethics 
Clearly, to rid the world of genetic diseases would be an objectively good outcome. From a consequentialist 
perspective, this would avoid significant suffering due to genetic conditions. Further, it is possible that PGD 
by polar body biopsy could prevent abortions by enabling parents to only create children they are willing 
to carry to term. However, this raises the question of whether it is ever appropriate to select for certain traits 
when attempting to conceive offspring via IVF. There are three general categories to examine here: 
diagnosis of genetic diseases before fertilization, diagnosis of genetic diseases after fertilization, and 
selection for ‘non-medical’ traits. 
First, since PGD by polar body biopsy occurs before fertilization, it avoids questions of personhood and 
gets at the simplest ethical question around medical genetic selection, namely, to what extent artificial 
selection among humans is ever acceptable. However, the relevance of this issue is diminished given the 
limited applications of polar body biopsy as addressed above. As such, a full treatment of this scenario is 
beyond the scope of this paper, but it is crucial to keep this central question in mind when looking at the 
following cases. 
Second, PGD based on cleavage-stage or blastocyst biopsy may be problematic since selecting only healthy 
embryos to implant inevitably results in the discard of affected embryos. If life begins at conception, this is 
tantamount to murder, though the sterile and impressive environment of the laboratory obscures this reality. 
The discard of embryos also breaks the Kantian imperative to treat people as ends in themselves and never 
merely as means only. Though PGD is intended to provide the best life for a child by choosing a child who 
doesn’t suffer from genetic diseases, it may prematurely end the lives of those that do. 
Further, while genetic diseases unfortunately cause significant suffering to many, it is also clear that many 
individuals affected by genetic diseases and disabilities live happy and productive lives. Some have argued 
that the normalization of PGD to select against embryos with genetic diseases and disabilities may cause 
further discrimination against and stigmatization of individuals with these conditions. It is also crucial to 
consider what conditions qualify to be treated as debilitating conditions eligible for PGD, as this technique 
could easily become a slippery slope into practical eugenics. 
On the other hand, it is also interesting to consider the rare but real situations in which parents choose to 
implant the ‘affected’ embryo rather than the ‘normal’ one. For example, some deaf couples “regard 
deafness as a distinctive culture rather than a disability” and would prefer to raise a deaf child in that 
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community.58 According to a 2008 study, when PGD was still a relatively young technology, 3% of IVF 
clinics offering PGD provided diagnoses for parents wishing to select for a genetic disease or disability,59 
a number that has undoubtedly increased in the eleven years since. Many raise here the child’s right to an 
open future (unlimited by disability that can be avoided), but it is worth noting that parents already make 
many, many decisions on behalf of their children, making this a tricky line to draw. 
Controversy has also arisen over parents using PGD to conceive a child who is an immunological match 
for an ill sibling. The human leukocyte antigen (HLA) complex is a series of genes that encode the major 
histocompatibility complex (MHC) proteins that mark the surface of a cell to identify it to the immune 
system. According to the aforementioned 2008 survey, 6% of IVF-PGD clinics have provided HLA typing 
to have a child who is a compatible donor for an existing child.60 Typically, the stem cells from the child 
left in the umbilical cord -- usually discarded -- are harvested to be used to treat the older sibling,61 meaning 
there is no physical trauma to the child during development or after birth. 
Some are concerned by this situation, as the second child is seemingly brought into the world primarily to 
serve as a donor for the first, sometimes in cases in which parents were not planning to conceive an 
additional child. However, there is little available evidence that unplanned children are less loved generally; 
some have even argued that donor children should feel a sense of pride for having contributed in this way 
to the family. Critics see HLA typing as using a child as a means rather than an end, but others maintain 
that the Kantian imperative only prohibits using a person as a means only, and parents would typically see 
their second child -- even if not a part of their original plan -- as an end in him/herself as well. It is also 
worth considering that many parents in this situation would otherwise attempt to have a child to serve as a 
donor by natural birth; PGD in conjunction with IVF simply makes the match more likely. However, it is 
still crucial to remember that in this situation, the unused embryos are usually discarded, and the saving of 
one life doesn’t outweigh the destruction of several others. 
Finally, PGD is often used for sex selection. This can be for medical reasons, such as avoiding an X-linked 
disease, or simply to satisfy parental preference. Usually, preferential sex selection occurs when parents 
already have a child (or children) of one gender and wish for their next child to be the opposite gender. 
Sometimes, however, in cultures where children of one gender are considered of greater value, sex selection 
can be the product of outright discrimination. For this reason, many countries have outlawed non-medical 
sex selection; the United States is one of only a few countries that still allows this practice.62 
Clearly, the slippery slope into non-medical applications of PGD is already becoming evident. As scientific 
understanding of the human genome has steadily increased over the last several decades, the capacity to 
select for non-medical traits has and will continue to grow. Further, the line between medical and non-
medical traits is a blurry one, and, paradoxically, growing blurrier as our knowledge increases. Is selecting 
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against a 70% increased risk of leukemia a medical treatment? What about 20%? What about genetic 
predispositions to mental illness such as depression? What about genetic factors that may be linked to 
violent behavior? What about superficial factors, such as height, that could lead to increased likelihood of 
bullying, which could result in anxiety?  
While this level of specificity is currently in the future, it is not so far off as many suppose. In November 
2018, Chinese researcher He Jiankui announced the birth of twin girls edited by CRISPR and implanted by 
IVF. This crossed the line of selection into the realm of engineering. While almost universally condemned 
by the scientific community, Jiankui’s work opened the door to an inevitable future. CRISPR kits can be 
purchased on Amazon for less than $200, and self-proclaimed ‘biohackers’ are already exploring its 
potential. This is no longer new and state-of-the-art technology. The question is only when it becomes 
acceptable in the professional as well as clandestine laboratory; it may be a matter of just a few years.  
While CRISPR and other gene therapies bring their own set of ethical conundrums beyond the scope of this 
paper, it is crucial to consider where the technology is headed in order to clarify our thinking on what we 
have now. Concerns over modifications to the germ line, the line between medicine and preference, just 
distribution of resources, and the slippery slope into eugenics are all real, significant questions that should 
be answered before scientists like Jiankui answer them for us.  
Ethics of economy: IVF and insurance incentives 
IVF is not only a complex and involved procedure, but an expensive one as well. Each cycle typically costs 
between $10,000-$15,000 out of pocket,63 but the average couple has only a 29.5% chance of conceiving 
on the first cycle.64 For hundreds of thousands of couples every year, it seems, the mere hope of conceiving 
a child is priceless -- or at least close enough to justify the cost. However, for many couples experiencing 
infertility, financial realities close the door to this possible treatment. Others have bankrupted themselves 
pursuing fruitless treatment, falling victim to the sunk-costs mentality that surely the next cycle would bring 
results. The pain of real financial barriers to conceiving children has led some to advocate for insurance 
coverage of advanced reproductive technologies (ART), including IVF.  
Insurance coverage of ART is controversial -- not only because of the ethical issues involved, but also the 
complex policy decisions and compromises required in application. Infertility coverage isn’t skimmed off 
the top of insurance company profits; it comes from either raising the cost of insurance for all participants 
or from reducing the coverage of other conditions. It’s worth considering where the money comes from. 
Despite the very real emotional pain of infertility, is it a significant enough health condition to justify 
diverting funds from other medical treatments? On the other hand, is it just to restrict ART to those who 
can afford its steep price tag? 
Nine U.S. states have mandated insurance coverage for IVF, reducing out-of-pocket costs to only about 
$2,000-$3,000 per cycle.65 However, infertility coverage brings with it a knot of policy issues that have to 
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be untangled. What happens when insurer and patient interests collide over when and how treatment should 
be carried out? For example, since multiple embryos are often implanted at once to increase the chance of 
pregnancy, IVF births have significantly greater likelihood of twins, triplets, etc. compared to traditional 
pregnancy. In fact, IVF patients constitute more than half of all total multiple births.66 While covered almost 
entirely by insurance, these multiple births cost four to sixteen times as much as single births even without 
including the cost of IVF,67 and may cause significant health risks to the mother.68 Patients, wanting to 
reduce costs and minimize invasive procedures, are more likely to pursue aggressive treatment and implant 
multiple embryos; insurers, wanting to save money in the long run, are more likely to advocate single 
implantation, even if it takes more cycles to achieve pregnancy. Innovative solutions to this quandary have 
been proposed, but this is just one of many unforeseen policy questions that will have to be answered by 
practitioners, lawmakers, and ethicists alike. 
Concerns have also been raised over the commercial interests associated with IVF and other advanced 
reproductive technologies. For instance, feminist scholar Anne Donchin has criticized the role of fertility 
clinics, health care practitioners, and scientific researchers (all of whom have a financial stake in the use of 
IVF) in raising fears over the infertility ‘epidemic.’ Encouraging insurers and patients to consider infertility 
as a disease, in Donchin’s view, subtly leads couples struggling with infertility to consider themselves sick 
and in need of a cure, rather than fully considering all the options. This problem is compounded by the 
close ties that bind childbearing to family and identity, especially for women. Donchin writes, 
Repeatedly, from physicians and other professionals with related interests, infertile women are urged to fulfill 
their "full reproductive potential" regardless of economic, psychological or bodily cost. … The inability to 
produce a child at will, once deemed inevitable and accepted with resignation, is more likely to be regarded 
now as a surmountable impediment to personal self-fulfillment. Even adoption, once an obvious alternative 
for aspiring parents unable to conceive, is now more likely to be viewed as a last resort, to be pursued only 
after all medical approaches to the production of biologically related children have been exhausted.69 
Some have even suggested that fertility clinics are incentivized to promote costly IVF procedures over less 
expensive alternatives that could equally or better serve the patient’s interests. The Australian clinic Monash 
IVF’s code of conduct explicitly states that clinicians should recognize that their primary obligation is to 
the company and its shareholders -- not to patients.70 While this is a broader topic than IVF itself, spanning 
the rising trend toward medical consumerism, the fertility industry is particularly affected as a sector that 
is 1) relatively immature, 2) debatably not treating ‘disease’ per se, and 3) closely tied to very expensive 
and currently trendy treatment options. 
It is worth carefully considering what kind of behavior we incentivize, and what those incentives say about 
our society and human ontology. How does IVF affect the relationships among patients, practitioners, and 
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insurers? If insurance covers IVF, should it also cover adoption? What does treating infertility as a disease 
say about the significance of reproduction? What is the role of biology in family?  
Conclusion 
The pain of infertility is a difficult reality for many couples. IVF promises great hope as a new technology 
that surmounts barriers never before crossed. However, many see the moral cost of this technology as 
severe: not only does the normalization of IVF alter the metaphysical understanding of marriage, 
procreation, and family, it also results in the destruction of innumerable embryos every year, small human 
lives that are discarded as extra and unwanted. Selective implantation, the use of donors and surrogates, 
new combinations of gametes and somatic cells, PGD, CRISPR, and even the use of IVF itself may shift 
our sails toward stormy seas. Present decisions drive future developments; short-term justifications shape 
long-term values. Inertia is the enemy when direction determines destination. 
IVF’s promise provides powerful hope, and addressing this sensitive topic requires empathy, compassion, 
and grace. Yet as we seek solutions to the pain of infertility, let us beware of creating new problems we are 
unprepared to address. In answering medical questions, we cannot stop asking ethical ones.  
  
24 
The Ethics of IVF 
 
 
Bibliography 
Alasmari, Wardah, Fawaz Edris, Zainab Albar, Mamdoh Eskandar, Camellia Sultan, Amer Alboush, and 
Abdulaziz Alasmari. "Comparable Reproductive Outcomes of ICSI for Couples with Unexplained 
Infertility and Couples with Male Factor Infertility." Middle East Fertility Society Journal 23, 
(2018): 393-398.  
Baruch, Susannah, David Kaufman, and Kathy Hudson. "Genetic Testing of Embryos: Practices and 
Perspectives of US in Vitro Fertilization Clinics." Fertility and Sterility 89, (2008): 1053-1058. 
Cohen, Cynthia. "Reproductive Technologies: V. Gamete Donation." In Encyclopedia of Bioethics, 2004. 
Congregation for the Doctrine of the Faith. "Dignitas Personae." (2008). 
De Melo-Martín, Immaculada. "How Best to Protect the Vital Interests of Donor-Conceived Individuals: 
Prohibiting Or Mandating Anonymity in Gamete Donations?" Reproductive Biomedicine & Society 
Online 3, (2016): 100-108. 
Donchin, Anne. "Health Care Access, Costs, and Treatment Dynamics: Evidence from in Vitro 
Fertilization." Journal of Medicine and Philosophy 21, (1996): 475-498. 
George, Robert. "What's Sex Got to do with it? Marriage, Morality, and Rationality." 
Goldworth, Ammon. "The Ethics of in Vitro Fertilization." Pediatrics in Review 20, (1999): 28-31. 
Hamilton, Barton, Emily Jungheim, Brian McManus, and Juan Pantano. "Health Care Access, Costs, and 
Treatment Dynamics: Evidence from in Vitro Fertilization." American Economic Review no. 108 
(2018): 3725-3777. https://doi.org/10.1257/aer.20161014. 
Harrison, Sarah Ellys, Berna Sozen, Neophytos Christodoulou, Christos Kyprianou, and Magdalena 
Zernicka-Goetz. "Assembly of Embryonic and Extraembryonic Stem Cells to Mimic Embryogenesis 
in Vitro." Science 14, (2017). 
Hymers, John. "Not a Modest Proposal: Peter Singer and the Definition of Person." Ethical Perspectives 
6, (1999): 126-138. 
Jones, D. A. "Christian Ethics, Roman Catholic." In Encyclopedia of Applied Ethics, Second Edition, 
edited by Chadwick, Ruth, 435-444: Elsevier, Inc., 2012. 
Klenov, V. E. "Live Birth and Multiple Birth Rates in US in Vitro Fertilization Treatment using Donor 
Oocytes: A Comparison of Single-Embryo Transfer and Double-Embryo Transfer." Journal of 
Assisted Reproduction and Genetics 35, (2018): 1657-1664. 
Kokkali, G., J. Traeger-Synodinos, C. Vrettou, D. Stavrou, G. M. Jones, D. S. Cram, E. Makrakis, A. O. 
Trounson, E. Kanavakis, and K. Pantos. "Blastocyst Biopsy Versus Cleavage Stage Biopsy and 
Blastocyst Transfer for Preimplantation Genetic Diagnosis of Β-Thalassaemia: A Pilot Study." 
Human Reproduction 22, (2007): 1443-1449. 
Lacham-Kaplan, Orly, Rob Daniels, and Alan Trounson. "Fertilization of Mouse Oocytes using Somatic 
Cells as Male Germ Cells." Reproductive BioMedicine Online 3, (2001): 205-211. 
Lai, Qiaohong, Hanwang Zhang, Guijing Zhu, Yufeng Li, Lei Jin, Long He, Zhijun Zhang, et al. 
"Comparison of the GnRH Agonist and Antagonist Protocol on the Same Patients in Assisted 
Reproduction during Controlled Ovarian Stimulation Cycles." International Journal of Clinical and 
Experimental Pathology 6, (2013): 1903-1910. 
25 
Bioethics in Faith and Practice ⦁ 2019 ⦁ Volume 4 ⦁ Number 1 
 
Liu, Hui, Haibin Zhao, Guanling Yu, Mei Li, Shuiying Ma, Haozhen Zhang, and Keliang Wu. 
"Conventional in Vitro Fertilization (IVF) Or Intracytoplasmic Sperm Injection (ICSI): Which is 
Preferred for Advanced Age Patients with Five Or Fewer Oocytes Retrieved?" Archives of 
Gynecology and Obstetrics 297, (2018): 1301-1306. 
MacLennan, Marie, James Crichton, Christopher Playfoot, and Ian Adams. "Oocyte Development, 
Meiosis and Aneuploidy." Seminars in Cell and Developmental Biology 45, (2015): 68-76. 
Mayes, Christopher, Brette Blakely, Ian Kerridge, Paul Komesaroff, Ian Olver, and Wendy Lipworth. 
"On the Fragility of Medical Virtue in a Neoliberal Context: The Case of Commercial Conflicts of 
Interest in Reproductive Medicine." Theoretical Medicine and Bioethics 37, (2016): 97-111. 
Meerabeau, Liz. "Consumerism and Health Care: The Example of Fertility Treatment." Journal of 
Advanced Nursing 27, (1998): 721-729. 
Meilaender, Gilbert. Bioethics: A Primer for Christians. 3rd ed. Grand Rapids, Michigan: Eerdmans, 
2013. 
Montag, Markus, Maria Köster, Thomas Strowitzki, and Bettina Toth. "Polar Body Biopsy." Fertility and 
Sterility 3, (2013): 603-607. 
Moutou, C., V. Goossens, E. Coonen, M. De Rycke, G. Kokkali, P. Renwick, S. B. SenGupta, K. Vesela, 
and J. Traeger-Synodinos. "ESHRE PGD Consortium Data Collection XII: Cycles from January to 
December 2009 with Pregnancy Follow-Up to October 2010." Human Reproduction 29, (2014): 
880-903. 
Niederberger, Craig, Antonio Pellicer, Jacques Cohen, David K. Gardner, Gianpiero D. Palermo, Claire 
L. O’Neill, Stephen Chow, et al. "Forty Years of IVF." Fertility and Sterility 110, (2018): 185-324. 
Ombelet, Willem and Johan Van Robays. "Artificial Insemination History: Hurdles and Milestones." 
Facts, Views & Vision in ObGyn 7, (2015): 137. 
Ravelingien, An, Veerle Provoost, Elia Wyverkens, Ann Buysse, Petra De Sutter, and Guido Pennings. 
"Recipients' Views on Payment of Sperm Donors." Reproductive BioMedicine Online 31, (2015): 
225-231. 
Rivron, Nicolas, Javier Frias-Aldeguer, Erik Vrij, Boisset, Jean-Charles Boisset, Jeroen Korving, Judith 
Vivié, et al. "Blastocyst-Like Structures Generated Solely from Stem Cells." Nature 557, (2018): 
106-111. 
Scott, Richard, Kathleen Upham, Eric Forman, Tian Zhao, and Nathan Treff. "Cleavage-Stage Biopsy 
significantly Impairs Human Embryonic Implantation Potential while Blastocyst Biopsy does Not: A 
Randomized and Paired Clinical Trial." Fertility and Sterility 100, (2013): 624-630. 
Sermon, Karen, André Van Steirteghem, and Inge Liebaers. "Preimplantation Genetic Diagnosis." The 
Lancet 363, (2004): 1633-1641. 
Seymour Fahmy, Melissa. "On the Supposed Moral Harm of Selecting for Deafness." Bioethics 25, 
(2011): 128-136. 
Shapiro, Daniel. "Payment to Egg Donors is the Best Way to Ensure Supply Meets Demand." Best 
Practice & Research Clinical Obstetrics & Gynaecology 53, (2018): 73-84. 
Smith, Andrew, Kate Tilling, Scott Nelson, and Debbie Lawlor. "Live-Birth Rate Associated with Repeat 
in Vitro Fertilisation Treatment Cycles." The Journal of the American Medical Association 314, 
(2015): 2654-2662. 
26 
The Ethics of IVF 
 
 
Steffen, N. "Core Values in Bioethics: A Natural Law Perspective." Ethics, Medicine, and Public Health 
2, (2016): 170-180. 
Suzuki, Toru, Maki Asami, Martin Hoffmann, Xin Lu, Miodrag Gužvić, Christoph Klein, and Anthony 
Perry. "Mice Produced by Mitotic Reprogramming of Sperm Injected into Haploid 
Parthenogenotes." Nature Communications 7, (2016): 1-15. 
Tannus, Samer, Yoni Cohen, Weon-Young Son, Tal Shavit, and Michael-Haim Dahan. "Cumulative Live 
Birth Rate Following Elective Single Blastocyst Transfer Compared with Double Blastocyst 
Transfer in Women Aged 40 Years and Over." Reproductive BioMedicine Online 35, (2017): 733-
738. 
Thornhill, Alan. Practice Manual of in Vitro Fertilization. New York: Springer, 2012. 
Tober, Diane. "Semen as Gift, Semen as Goods: Reproductive Workers and the Market in Altruism." 
Body and Society 7, (2001): 137-160. 
Wdowiak, Artur, Edyta Wdowiak, and Iwona Bojar. "Improving the Safety of the Embryo and the Patient 
during in Vitro Fertilization Procedures." Wideochir Inne Tech Maloinwazyjne 11, (2016): 137-143. 
  
